Supplant raised more capital funding in a round backed by American celebrity investors.

Supplant, a London, UK-based producer of an alterntive type of sugar, announced a $3 million funding extension to its series A round closed at the beginning of 2021.

The deal was closed in order to accomodate Ayesha Curry, Chris Paul and Ryan Shadrick Wilson as early stage investors, joining Series A investors Manta Ray, EQT, Khosla, Felicis, Coatue, Y Combinator, Agfunder, Melitas, Mills Fabrica and Sake Bosch.

Supplant, founded as Cambridge Glycoscience in 2017 by CEO Tom Simmons, developed a biotechnology platform that makes sugar substitutes and based on which it produces sugars from the waste materials of plants other than sugarcane.

The company was part of Y Combinator in the summer of 2018 and raised a total of $27 million including this round.